ROLE OF ENDOGENOUS INTERLEUKIN‐10 IN LOCAL AND DISTANT ORGAN INJURY AFTER VISCERAL ISCHEMIA‐REPERFUSION

&NA; The anti‐inflammatory cytokine interleukin (IL)‐10 has been detected in serum after visceral ischemiareperfusion injury and exogenous IL‐10 administration has been shown to attenuate the associated distant organ injury. This study was designed to examine the role that endogenous IL‐10 production plays on both local and distant organ injury after visceral ischemia‐reperfusion injury. Wild‐type and IL‐10−/−‐null C57BL/6 mice were subjected to 20 min of supraceliac aortic occlusion or sham laparotomy. Serum and lung tissue cytokine levels (tumor necrosis factor alpha, IL‐1&bgr;, IL‐6, KC/GRO, and IL‐10) were measured after reperfusion (1, 2, and/or 4 h) using either enzyme‐linked immunoassay or bioassay. Lung neutrophil infiltration and injury were quantified after reperfusion injury using myeloperoxidase concentration (2 h) and mean capillary permeability (4 h), respectively, whereas the direct liver injury was quantified with serum aspartate aminotransferase levels (1, 2, and 4 h). A subset of IL‐10−/−‐null animals was administered human recombinant IL‐10 before the visceral ischemia and lung MPO was measured after reperfusion (2 h). Visceral ischemia‐reperfusion in the wild‐type and IL‐10−/−‐null mice was associated with in an increase in both serum (IL‐1&bgr;, KC/GRO, IL‐6) and lung tissue (IL‐1&bgr;, KC/GRO) cytokine levels and resulted in lung neutrophil infiltration (myeloperoxidase), lung injury (mean capillary permeability) and liver injury (aspartate aminotransferase). The magnitude of the lung tissue cytokine response (IL‐1&bgr;, KC/GRO), neutrophil infiltration, and injury were greater in the IL‐10−/−‐null mice. Exogenous IL‐10 resulted in a decrease in the lung neutrophil infiltration in the IL‐10−/−‐null mice. The endogenous IL‐10 response to visceral ischemiareperfusion attenuates the associated lung neutrophil infiltration and injury but has no effect upon either the hepatic injury or the magnitude of the systemic inflammatory response. The beneficial effects of IL‐10 may be mediated by the inhibition of IL‐1&bgr; and KC/GRO through an endocrine rather than paracrine signal.

[1]  Y. Kotake,et al.  Antioxidant Amplifies Antibiotic Protection in the Cecal Ligation and Puncture Model of Microbial Sepsis Through Interleukin-10 Production , 2003, Shock.

[2]  C. Dohm,et al.  Early Interleukin-10 Treatment Improves Survival and Enhances Immune Function Only in Males After Hemorrhage and Subsequent Sepsis , 2002, Shock.

[3]  A. Levine,et al.  IL-10 is not protective in intestinal ischemia reperfusion injury. , 2002, The Journal of surgical research.

[4]  S. Berceli,et al.  Durability of antegrade synthetic aortomesenteric bypass for chronic mesenteric ischemia. , 2002, Journal of vascular surgery.

[5]  D. Carter,et al.  Characterization of a Murine Model of Endotoxin-Induced Acute Lung Injury , 2002, Shock.

[6]  Y. Kotake,et al.  Interleukin-10 Overexpression Mediates Phenyl-N-Tert-Butyl Nitrone Protection From Endotoxemia , 2002, Shock.

[7]  L. Moldawer,et al.  Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis1 , 2001, The Journal of Immunology.

[8]  H. Wong,et al.  Absence of endogenous interleukin 10 enhances early stress response during post-ischaemic injury in mice intestine , 2001, Gut.

[9]  L. Moldawer,et al.  The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair , 2000, Critical care medicine.

[10]  L. Moldawer,et al.  Interleukin-10 appearance following thoraco-abdominal and abdominal aortic aneurysm repair is associated with the duration of visceral ischaemia. , 2000, European Journal of Vascular and Endovascular Surgery.

[11]  L. Moldawer,et al.  ANTICYTOKINE THERAPIES FOR ACUTE INFLAMMATION AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: IL‐10 AND ISCHEMIA/REPERFUSION INJURY AS A NEW PARADIGM , 2000, Shock.

[12]  Z. Yang,et al.  Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. , 2000, Circulation.

[13]  A. Lentsch,et al.  Interleukin‐10 suppresses hepatic ischemia/reperfusion injury in mice: Implications of a central role for nuclear factor κB , 1999, Hepatology.

[14]  L. Moldawer,et al.  Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. , 1997, Journal of vascular surgery.

[15]  L. Moldawer,et al.  Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. , 1997, The Journal of surgical research.

[16]  L. Moldawer,et al.  VISCERAL ISCHEMIA‐REPERFUSION INJURY PROMOTES TUMOR NECROSIS FACTOR (TNF) AND INTERLEUKIN‐1 (IL‐1) DEPENDENT ORGAN INJURY IN THE MOUSE , 1996, Shock.

[17]  K. Rajewsky,et al.  Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. , 1995, The Journal of clinical investigation.

[18]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[19]  C. Valeri,et al.  Neutrophil and Nonneutrophil‐Mediated Injury in Intestinal Ischemia‐Reperfusion , 1993, Annals of surgery.

[20]  M. Baggiolini,et al.  Interleukin‐8, a chemotactic and inflammatory cytokine , 1992, FEBS letters.

[21]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[22]  L. Moldawer,et al.  Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. , 2002, Critical care medicine.

[23]  M. Krangel,et al.  Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. , 1992, Critical reviews in immunology.